IN2012DN02469A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02469A
IN2012DN02469A IN2469DEN2012A IN2012DN02469A IN 2012DN02469 A IN2012DN02469 A IN 2012DN02469A IN 2469DEN2012 A IN2469DEN2012 A IN 2469DEN2012A IN 2012DN02469 A IN2012DN02469 A IN 2012DN02469A
Authority
IN
India
Prior art keywords
compounds
disorders
abnormal
diseases
raf
Prior art date
Application number
Other languages
English (en)
Inventor
Shenlin Huang
Xianming Jin
Zuosheng Liu
Daniel Poon
John E Tellew
Yongqin Wan
Xing Wang
Yongping Xie
Original Assignee
Irm Llc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42782253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN02469(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc, Novartis Ag filed Critical Irm Llc
Publication of IN2012DN02469A publication Critical patent/IN2012DN02469A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
IN2469DEN2012 2009-08-28 2010-08-27 IN2012DN02469A (h)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23807309P 2009-08-28 2009-08-28
US31303910P 2010-03-11 2010-03-11
PCT/US2010/046930 WO2011025927A1 (en) 2009-08-28 2010-08-27 Compounds and compositions as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2012DN02469A true IN2012DN02469A (h) 2015-08-21

Family

ID=42782253

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2469DEN2012 IN2012DN02469A (h) 2009-08-28 2010-08-27

Country Status (49)

Country Link
US (12) US8501758B2 (h)
EP (2) EP2727918B1 (h)
JP (2) JP5475888B2 (h)
KR (1) KR101413392B1 (h)
CN (2) CN103896921B (h)
AR (1) AR077975A1 (h)
AU (1) AU2010286569C1 (h)
BR (1) BR112012004453B1 (h)
CA (1) CA2771775C (h)
CL (1) CL2012000340A1 (h)
CO (1) CO6612222A2 (h)
CR (1) CR20120102A (h)
CU (1) CU24110B1 (h)
CY (3) CY1118452T1 (h)
DK (2) DK2470526T3 (h)
DO (1) DOP2012000051A (h)
EA (2) EA201500175A1 (h)
EC (2) ECSP12011700A (h)
ES (2) ES2610825T3 (h)
GE (1) GEP20146102B (h)
GT (1) GT201200053A (h)
HN (1) HN2012000441A (h)
HR (2) HRP20140799T1 (h)
HU (3) HUE032847T2 (h)
IL (1) IL218084A (h)
IN (1) IN2012DN02469A (h)
JO (1) JO3002B1 (h)
LT (3) LT2727918T (h)
LU (2) LUC00101I2 (h)
MA (1) MA33604B1 (h)
ME (2) ME01860B (h)
MX (1) MX2012002546A (h)
MY (1) MY156259A (h)
NI (1) NI201200029A (h)
NL (1) NL300973I2 (h)
NO (2) NO2019012I1 (h)
NZ (1) NZ598924A (h)
PE (1) PE20120861A1 (h)
PL (2) PL2727918T3 (h)
PT (2) PT2727918T (h)
RS (2) RS53489B1 (h)
SG (2) SG178351A1 (h)
SI (2) SI2470526T1 (h)
SM (3) SMT201700036T1 (h)
TN (1) TN2012000081A1 (h)
UA (1) UA112285C2 (h)
UY (1) UY32860A (h)
WO (1) WO2011025927A1 (h)
ZA (1) ZA201202020B (h)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
ES2674682T3 (es) 2010-02-25 2018-07-03 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
US8907270B2 (en) 2010-06-30 2014-12-09 Schlumberger Technology Corporation Method and apparatus for gain regulation in a gamma detector
MX354725B (es) * 2011-11-11 2018-03-16 Novartis Ag Metodo de tratamiento de una enfermedad proliferativa.
SI2782557T1 (sl) * 2011-11-23 2019-02-28 Array Biopharma, Inc., Farmacevtske formulacije
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
JP2015506347A (ja) * 2011-12-23 2015-03-02 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. ヘテロアリールおよびその使用
JP6348898B2 (ja) 2012-03-28 2018-06-27 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Raf阻害剤に対する耐性を付与するc−raf突然変異体
CN104640857B (zh) 2012-07-18 2017-07-04 圣路易斯大学 作为整合素拮抗剂的β氨基酸衍生物
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
MX359403B (es) * 2012-08-07 2018-09-26 Novartis Ag Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa.
KR20240146112A (ko) 2012-08-17 2024-10-07 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
WO2014047330A1 (en) * 2012-09-19 2014-03-27 Jean-Michel Vernier Novel raf kinase inhibitors
UA115151C2 (uk) 2012-11-08 2017-09-25 Новартіс Аг Фармацевтична комбінація, що містить інгібітор b-raf та інгібітор деацетилази гістонів, та її застосування при лікуванні проліферативних захворювань
CA2907704C (en) 2013-03-21 2023-01-10 Giordano Caponigro Combination therapy for reversing b-raf inhibitor resistance comprising a second inhibitor based on genetic alterations
TWI634114B (zh) 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
AU2014274093B2 (en) 2013-05-30 2018-11-08 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
CA3240745A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
CA2934866A1 (en) * 2013-12-23 2015-07-02 Novartis Ag Pharmaceutical combinations
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
DE102015103158A1 (de) 2014-03-04 2015-09-10 Bergische Universität Wuppertal Verbindungen für die Behandlung des Melanoms
KR20240110004A (ko) 2014-03-14 2024-07-12 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
WO2015175846A2 (en) * 2014-05-16 2015-11-19 University Of Massachusetts Treating chronic myelogenous leukemia (cml)
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US10167279B2 (en) * 2014-09-12 2019-01-01 Novartis Ag Compounds and compositions as RAF kinase inhibitors
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017079116A2 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
EP4424322A3 (en) 2015-12-17 2025-04-16 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2017117538A1 (en) 2015-12-30 2017-07-06 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
FI3463345T3 (fi) 2016-06-03 2023-01-31 Farmaseuttisia yhdistelmiä
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JP7076741B2 (ja) 2016-12-27 2022-05-30 国立研究開発法人理化学研究所 Bmpシグナル阻害化合物
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107540699A (zh) * 2017-10-16 2018-01-05 康化(上海)新药研发有限公司 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2020011141A1 (zh) * 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
WO2020231976A1 (en) 2019-05-16 2020-11-19 Eli Lilly And Company Triple combination of an erk1/2 inhibitor with a braf inhibitor and an egfr inhibitor for use in the treatment of brafv600e colorectal cancer
CN114746419B (zh) 2019-12-05 2023-10-24 国家医疗保健研究所 N-(3-(5-(嘧啶-4-基)噻唑-4-基)苯基)磺酰胺化合物及其用作braf抑制剂的用途
PE20231651A1 (es) 2020-06-09 2023-10-17 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
WO2022036176A1 (en) 2020-08-13 2022-02-17 Albert Einstein College Of Medicine N-cyclyl-sulfonamides useful for inhibiting raf
MX2023003867A (es) 2020-10-05 2023-04-18 Pf Medicament Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii.
EP4308935A1 (en) 2021-03-18 2024-01-24 Novartis AG Biomarkers for cancer and methods of use thereof
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
KR102699226B1 (ko) 2021-06-09 2024-08-27 에프. 호프만-라 로슈 아게 암 치료를 위한 병용요법
CN114557977A (zh) * 2022-02-16 2022-05-31 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024163166A1 (en) * 2023-01-30 2024-08-08 5Metis, Inc. Boron containing compounds and their uses
CN116396222A (zh) * 2023-04-10 2023-07-07 上海睿腾医药科技有限公司 一种康奈非尼中间体1-(3-氨基-1-异丙基-1h-吡唑-4-基)乙-1-酮的合成方法
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104250A (en) * 1976-08-11 1978-08-01 Borg-Warner Corporation Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
DE3571974D1 (en) 1984-12-06 1989-09-07 Pfizer Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
EP0952770A4 (en) 1995-09-07 1999-12-22 Fuisz Technologies Ltd SYSTEM FOR MAKING SUBSTANTIALLY NON-SOLUBLE BIOALTERANT AGENTS BIOAVAILABLE
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
EP0910401A1 (en) 1996-05-23 1999-04-28 Applied Research Systems ARS Holdings N.V. Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EE9900527A (et) 1997-05-22 2000-06-15 G.D. Searle & Co. Substitueeritud pürasoolid kui p38 kinaasi inhibiitorid
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
JP5159012B2 (ja) 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物
AU2001285349A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
PT1441714E (pt) 2001-10-25 2008-03-10 Novartis Ag Combinações compreendendo um inibidor selectivo da ciclo-oxigenase 2
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス(ケンブリッジ)リミテッド 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用
PT1482932E (pt) 2002-03-13 2010-01-12 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
EP1682181A2 (en) 2003-09-23 2006-07-26 Novartis AG Combination of a vegf receptor inhibitor with a chemotherapeutic agent
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
CA2551948A1 (en) 2004-01-09 2005-07-28 Novartis Ag Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
JP4688876B2 (ja) 2004-06-10 2011-05-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
MX2007011435A (es) 2005-03-17 2007-12-05 Novartis Ag N-[3-(1-amino-5,6,7,8-tetrahidro-2,4,4b-triazafluoren-9-il)-fenil ]-benzamidas como inhibidores de cinasa de tirosina/treonina, en particular de cinasa b-raf.
US20070099856A1 (en) 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
EP1934185A1 (en) 2005-08-12 2008-06-25 Synta Pharmaceuticals Corporation Pyrazole compounds that modulate hsp90 activity
CA2619035A1 (en) 2005-08-22 2007-03-01 Novartis Ag Pharmaceutical compositions
JP2009506040A (ja) 2005-08-26 2009-02-12 スミスクライン・ビーチャム・コーポレイション オーロラキナーゼのピリミジニル−ピラゾール阻害剤
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
CA2643066A1 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
MX2008012716A (es) 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
SG174772A1 (en) 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
EP2068880B1 (en) 2006-09-18 2012-04-11 Boehringer Ingelheim International GmbH Method for treating cancer harboring egfr mutations
AU2007305016B2 (en) 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
CA2664147A1 (en) * 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
EP2491923A3 (en) 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
EP2183243A2 (en) * 2007-08-01 2010-05-12 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
BRPI0818340A2 (pt) 2007-10-19 2015-04-22 Abbott Gmbh & Co Kg Produto de dispersão sólida de fármacos baseados em n-aril uréia
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
MX2010010317A (es) * 2008-03-21 2010-10-04 Novartis Ag Compuestos heterociclicos novedosos y usos de los mismos.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN102105459B (zh) * 2008-07-24 2014-09-10 内尔维阿诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑类
KR20110038159A (ko) 2008-07-28 2011-04-13 길리애드 사이언시즈, 인코포레이티드 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
BRPI0920608A2 (pt) 2008-09-29 2019-09-24 Boehringer Ingelheim Int compostos quimicos
PL2346495T5 (pl) 2008-10-07 2024-06-10 Kudos Pharmaceuticals Limited Preparat farmaceutyczny 514
US20110293750A1 (en) * 2008-11-11 2011-12-01 Yale University Activated wnt-beta-catenin signaling in melanoma
WO2010070060A1 (en) 2008-12-19 2010-06-24 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
ES2679379T3 (es) * 2009-06-15 2018-08-24 Nerviano Medical Sciences S.R.L. Derivados de pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa
KR101256018B1 (ko) * 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
EA023942B1 (ru) 2010-01-27 2016-07-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
US9114137B2 (en) 2010-08-03 2015-08-25 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
WO2012128709A1 (en) 2011-03-21 2012-09-27 Valcuria Ab A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof.
US20140113919A1 (en) 2011-06-14 2014-04-24 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
MX354725B (es) 2011-11-11 2018-03-16 Novartis Ag Metodo de tratamiento de una enfermedad proliferativa.
SI2782557T1 (sl) 2011-11-23 2019-02-28 Array Biopharma, Inc., Farmacevtske formulacije
UA115151C2 (uk) 2012-11-08 2017-09-25 Новартіс Аг Фармацевтична комбінація, що містить інгібітор b-raf та інгібітор деацетилази гістонів, та її застосування при лікуванні проліферативних захворювань
US10576680B2 (en) 2015-11-19 2020-03-03 The Boeing Company Modular thermoforming system

Also Published As

Publication number Publication date
JP5475888B2 (ja) 2014-04-16
ES2492499T3 (es) 2014-09-09
CL2012000340A1 (es) 2012-08-17
HUS1900013I1 (hu) 2019-04-29
CA2771775A1 (en) 2011-03-03
IL218084A0 (en) 2012-04-30
ME02684B (me) 2017-06-20
LUC00101I1 (h) 2019-02-13
US20160122324A1 (en) 2016-05-05
CN102725283B (zh) 2014-02-26
HN2012000441A (es) 2015-01-05
RS53489B1 (en) 2015-02-27
CR20120102A (es) 2012-05-02
EP2470526A1 (en) 2012-07-04
BR112012004453A2 (pt) 2021-03-09
WO2011025927A1 (en) 2011-03-03
NI201200029A (es) 2012-05-29
GT201200053A (es) 2014-03-27
NZ598924A (en) 2013-07-26
US9850230B2 (en) 2017-12-26
NO2019011I1 (no) 2019-03-05
US20160280686A1 (en) 2016-09-29
DK2470526T3 (da) 2014-08-25
EP2727918B1 (en) 2016-10-12
CY2019014I2 (el) 2019-11-27
ECSP23004573A (es) 2023-04-28
LTPA2019006I1 (lt) 2019-03-25
US8501758B2 (en) 2013-08-06
KR20120062839A (ko) 2012-06-14
PT2470526E (pt) 2014-09-01
NL300973I2 (nl) 2022-05-05
US20180297985A1 (en) 2018-10-18
ME01860B (me) 2014-12-20
CN102725283A (zh) 2012-10-10
CA2771775C (en) 2015-01-20
US20130296318A1 (en) 2013-11-07
HUE032847T2 (hu) 2017-11-28
HRP20170005T1 (hr) 2017-03-10
SMT201400133B (it) 2014-11-10
NL300973I1 (h) 2019-03-27
US20200323852A1 (en) 2020-10-15
UA112285C2 (uk) 2016-08-25
US20230116233A1 (en) 2023-04-13
UY32860A (es) 2011-03-31
MA33604B1 (fr) 2012-09-01
US9850229B2 (en) 2017-12-26
CY1118452T1 (el) 2017-07-12
CN103896921B (zh) 2016-02-24
MY156259A (en) 2016-01-29
SI2470526T1 (sl) 2014-09-30
EA201500175A1 (ru) 2015-05-29
CO6612222A2 (es) 2013-02-01
SMT201700036B (it) 2017-03-08
EP2470526B1 (en) 2014-05-28
MX2012002546A (es) 2012-04-11
LTC2470526I2 (lt) 2020-04-27
HUS1900012I1 (hu) 2019-04-29
US10005761B2 (en) 2018-06-26
HK1167390A1 (en) 2012-11-30
JP6045519B2 (ja) 2016-12-14
US10568884B2 (en) 2020-02-25
AR077975A1 (es) 2011-10-05
JP2013503186A (ja) 2013-01-31
LUC00101I2 (h) 2020-01-23
SG178351A1 (en) 2012-03-29
DK2727918T3 (da) 2017-01-23
CY2019014I1 (el) 2019-11-27
EA025222B1 (ru) 2016-12-30
JP2014098022A (ja) 2014-05-29
AU2010286569A1 (en) 2012-04-12
LUC00102I2 (h) 2024-05-21
HRP20140799T1 (hr) 2014-11-07
ES2610825T3 (es) 2017-05-03
US20160280687A1 (en) 2016-09-29
PE20120861A1 (es) 2012-07-14
US10576080B2 (en) 2020-03-03
RS55568B1 (sr) 2017-05-31
SI2727918T1 (sl) 2017-02-28
GEP20146102B (en) 2014-05-27
SMT201700036T1 (it) 2017-03-08
DOP2012000051A (es) 2012-05-31
CY2019013I1 (el) 2019-11-27
LT2727918T (lt) 2017-01-25
ZA201202020B (en) 2012-12-27
PL2470526T3 (pl) 2014-10-31
NO2019012I1 (no) 2019-03-05
CN103896921A (zh) 2014-07-02
CU20120034A7 (es) 2012-06-21
BR112012004453B1 (pt) 2022-04-26
US20180297986A1 (en) 2018-10-18
SG10201405311TA (en) 2014-09-26
CY2019013I2 (el) 2019-11-27
AU2010286569C1 (en) 2019-11-28
PL2727918T3 (pl) 2017-06-30
BR112012004453A8 (pt) 2021-06-08
EA201200373A1 (ru) 2012-09-28
KR101413392B1 (ko) 2014-06-27
CU24110B1 (es) 2015-07-30
US20110306625A1 (en) 2011-12-15
PT2727918T (pt) 2017-01-20
IL218084A (en) 2016-11-30
ECSP12011700A (es) 2012-03-30
TN2012000081A1 (en) 2013-09-19
US20160263113A1 (en) 2016-09-15
US9593099B2 (en) 2017-03-14
US9593100B2 (en) 2017-03-14
US9314464B2 (en) 2016-04-19
USRE49556E1 (en) 2023-06-20
EP2727918A1 (en) 2014-05-07
LTPA2019005I1 (lt) 2019-03-25
JO3002B1 (ar) 2016-09-05
AU2010286569B2 (en) 2013-10-10
US20160120866A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
IN2012DN02469A (h)
PH12020550450A1 (en) Certain chemical entities, compositions and methods
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
IN2012DN02471A (h)
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
IN2012DN01961A (h)
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MY165728A (en) Selective glycosidase inhibitors and uses thereof
PH12014500351B1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
TW200637547A (en) Compounds and compositions as protein kinase inhibitors
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MY172151A (en) Certain chemical entities, compositions and methods
DE602006016449D1 (h)
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity